|
|
|
|
318
|
Wed, 8/11/2021,
3:30 PM -
5:20 PM
|
Virtual
|
|
Adaptive (and Other) Clinical Trial Designs — Contributed Speed
|
|
Biopharmaceutical Section
|
|
Chair(s): Theodore Lystig, BridgeBio
|
|
|
|
3:35 PM
|
Algorithms for Minimization Randomization and the Implementation with an R Package
Man (Mandy) Jin, AbbVie Inc
|
|
3:40 PM
|
A Bayesian Adaptation Method for Clinical Trials Under Nonproportional Hazards
Li Yu, Merck & Co.; Yue Shentu, Merck Sharp & Dohme; Xieyang Jia, Merck & Co.
|
|
3:45 PM
|
Changing Frequency of Analyses with Multiple Endpoints in Group-Sequential Clinical Trials
Koko Asakura, National Cerebral and Cardiovascular Center; Toshimitsu Hamasaki, George Washington University Biostatitics Center; Diane Uschner, George Washington University; Frank Bretz, Novartis AG
|
|
3:50 PM
|
Evaluating Two-Stage Adaptive Designs with Data-Driven Biomarker Selection
Sarah E Johnston, OUHSC Hudson College of Public Health; Ilya Lipkovich, Eli Lilly; Daniel E Zhao, OUHSC Hudson College of Public Health
|
|
3:55 PM
|
A Novel Statistical Test for Treatment Differences in Clinical Trials Using a Response Adaptive Forward Looking Gittins Index Rule
Sofia Villar, University of Cambridge; Thomas Jaki, Lancaster University; Helena Geys, Janssen Pharmaceutica; Helen Barnett, University of Cambridge
|
|
4:00 PM
|
Inference for a Two-Stage Enrichment Design
Zhantao Lin, Eli Lilly and Company; William Rosenberger, George Mason University; Nancy Flournoy, University of Missouri
|
|
4:05 PM
|
Application of Recursive Adaptive Design with Maximum Two Interim Analysis
Chuhan Zhou, Pacira Pharmaceuticals, Inc; Chao Li, Pacira Pharmaceuticals, Inc; Vincent Yu, Pacira Pharmaceuticals, Inc
|
|
4:10 PM
|
Allocation-Blind Adaptive Analysis Strategies for Randomized Trials with Serial Assessments of a Normally-Distributed Outcome
Phillip Schulte, Mayo Clinic; Kent Bailey, Mayo Clinic
|
|
4:15 PM
|
Faster and More Informative Phase 2b Dose-Ranging Trials Through Bayesian Uncertainty-Directed Designs with Model Averaging
Daniel Schwartz, University of Chicago; Yuan Ji, The University of Chicago
|
|
4:20 PM
|
Two-Stage Enrichment Clinical Trial Designs with Survival Outcomes and Adjustment for Misclassification in Predictive Biomarkers
Yanping Chen, Bristol Myers Squibb; Yong Lin, Rutgers University; Shou-En Lu, Rutgers School of Public Health and Cancer Institute of New Jersey
|
|
4:30 PM
|
Identifying Targeted Patients Population in Major Depressive Disorder by Enhanced Enrichment Design
Peter Zhang, Otsuka Pharmaceuticals Dev & Com, Inc.
|
|
4:35 PM
|
Properties of Log-Rank Test Following Covariate-Adaptive Randomization in Multi-Center Oncology Trials
Jerry J Li, Daiichi Sankyo Inc.; Olga M Kuznetsova, Merck & Co., Inc.; Gang Han, Department of Statistics, Iowa State University
|
|
4:40 PM
|
Bayesian Optimal Phase II Design for Basket Trials
Heng Zhou, Merck & Co., Inc; Tian He, Indiana University
|
|
4:45 PM
|
A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints
Yujie Zhao, Department of Biostatistics, University of Texas MD Anderson Cancer Center ; Rui (Sammi) Tang, Servier Pharmaceuticals; Yeting Du, Servier Pharmaceuticals; Ying Yuan, Department of Biostatistics, University of Texas MD Anderson Cancer Center
|
|
4:50 PM
|
Elastic Meta-Analytic-Predictive Prior for Dynamically Borrowing Information from Historical Data with Application to Biosimilar Clinical Trials
Wen Zhang, University of Texas Health Science Center at Houston; Ying Yuan, Department of Biostatistics, University of Texas MD Anderson Cancer Center; Zhiying Pan, Amgen, Inc.
|
|
4:55 PM
|
Adaptive Semiparametric Bayesian Borrowing Model in Basket Trials for Robust Inference and Decision-Making
Rachael Liu, Takeda Pharmaceuticals; Veronica Bunn, Takeda Pharmaceuticals; Jianchang Lin, Takeda Pharmaceuticals; Junjing Lin, Takeda Pharmaceuticals
|
|
5:00 PM
|
The Benefits of Conducting Bayesian Adaptive Designs in Dose-Finding Studies for Healthy Volunteers in Non-Oncology Clinical Trials
Carl Di Casoli, Sunovion Pharmaceuticals ; Hailong Cheng, Sunovion Pharmaceuticals; HoiWun (Natalie) Au, Sunovion Pharmaceuticals
|
|
5:05 PM
|
The Impact of Scientific Review on Early-Phase Clinical Trial Design
Bethany Jablonski Horton, University of Virginia
|
|
5:10 PM
|
A Clustering-Based Information Borrowing Under Local Multisource Exchangeability Assumption
Yilin Liu, Yale University; Wei Wei, Yale University
|
